• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Reducing the Risk of Comparator Sourcing

    Clinical Data Management

    Leveraging AI/ML Analytics for Better Clinical Development Decisions

    What is a Manufacturing Ecosystem and Why are They Growing?

    Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    Lifecore Biomedical Enters into $150M New Financing Deal

    WuXi Biologics Receives 2023 ISPE Facility of the Year Award

    Thermo Fisher Expands Steriles Facility in Asia-Pacific Region

    GHO Capital, Partners Group Invest in Sterling Pharma Solutions
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    "3 Key Trends" with Cory Lewis

    WuXi Biologics Receives 2023 ISPE Facility of the Year Award

    Thermo Fisher Expands Steriles Facility in Asia-Pacific Region

    GHO Capital, Partners Group Invest in Sterling Pharma Solutions
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    TraceLink, PharmaLink Partner to Simplify DSCSA Compliance

    "3 Key Trends" with Rafael Costa

    Schreiner MediPharm Introduces Tailored Tamper-Proof Closure Seals

    FDA Watch: Is Your Supply Chain at Risk?
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    "3 Key Trends" with Cory Lewis

    Lifecore Biomedical Enters into $150M New Financing Deal

    WuXi Biologics Receives 2023 ISPE Facility of the Year Award

    Thermo Fisher Expands Steriles Facility in Asia-Pacific Region
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA 2023 Inspection Roadmap: Is “Readiness” in Your Annual Objectives?

    FDA Watch: Are You Suitably Staffed?

    FDA Watch: Is Your Supply Chain at Risk?

    FDA Watch: CDER to Launch Guidance Snapshot Pilot Program

    "3 Key Trends" with Paul Josephs
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Almac Group

    LOTTE BIOLOGICS

    Quotient Sciences

    U.S. Pharmacopeia (USP)

    Lannett CDMO
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Almac Group

    LOTTE BIOLOGICS

    Quotient Sciences

    U.S. Pharmacopeia (USP)

    Lannett CDMO
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    FDA Watch

    Nitrosamines

    How to address these unwelcome guests in the pharmaceutical world

    Nitrosamines
    Aloka Srinivasan, Ph.D., Lachman Consultant Services05.07.19
    Nitrosamines are a family of carcinogens which are formed by the reaction of secondary amines, amides, carbamates, derivatives of urea with nitrite or other nitrogenous agents with the nitrogen in the +3 state.1 The common nature of the precursors and the facile nature of the nitrosation reactions under acidic pH have made nitrosamines one of the common and unwelcome guests in the world of consumer goods and pharmaceuticals—the one who comes uninvited, consumes our resources, and will simply not go away.

    The carcinogenic properties of nitrosamines have been known for over 50 years2 and there are several nitrosamines that have been tested for carcinogenicity and have shown activities, nitrosodimethylamine (NDMA) and nitrosodiethylamine (NDEA) and N-nitroso-N-methyl-4- aminobutyric acid (NMBA) being the well-known amongst these.3 Nitrosamines are classified by the ICH M7(R1) Guideline as Class 1 impurities, “known mutagenic carcinogens,” based on both rodent carcinogenicity and mutagenicity data.4 They are categorized by the International Agency for Cancer Research (IARC) as 2A – Probable Carcinogens5 based on data on a number of species studied. These two classifications (ICH M7(R1) versus IARC) should not be confused as they address the carcinogenicity from different angles. The ICH M7(R1) Class 1 finding limits the safety assessment approach/control options, which requires these to be at or below a compound-specific acceptable limit. The limits for nitrosamines in pharmaceuticals can be derived only from rodent study cancer potency data as the threshold of toxicological concern (TTC) approach is not acceptable to most regulatory agencies in the world.4

    Nitrosamines have recently re-surfaced in the pharmaceutical world due to FDA and other international agencies finding traces of these compounds in the angiotensin II receptor blockers (ARBs), commonly known as the “sartans.” The drugs involved are Valsartan, Losartan, Irbesartan, Azilsartan, Olmesartan, Eprosartan, Candesartan and Telmisartan.6 As of now, Valsartan and Losartan are the worst affected and several lots of these products have been recalled.7 Also, all pharmaceutical companies which have FDA approved “sartans” have been sent requests to evaluate the presence of nitrosamines in their products and communicate their findings to FDA.7 In addition, FDA has been working towards addressing the issue of nitrosamines in “sartans” and keeping the public informed about the actions being taken.7 FDA’s actions have included recalls of several lots of ARBs, providing of acceptable limits of the nitrosamines in the ARBs and also providing the sponsors with sensitive analytical methods for analysis.8 Following ICH M7(R1), safe levels of NDMA and NDEA have been calculated using the TD50 values from rodent carcinogenicity studies adjusted to represent a cancer risk of one excess cancer per 100,000 people exposed on a daily basis over a lifetime. FDA has currently provided safety limits for NDMA at 96 ng/day and NDEA at 26.5 ng/day.6 For NMBA, which was identified more recently, the safety level is determined at 96 ng/day.6

    However, for Losartan, FDA is currently accepting an interim specification of NMBA at 9.82 ppm versus 0.96 ppm, which would be the limit based on the TDI (total daily intake) of 96 ng/day.6 The basis of the acceptability of NMBA at levels up to 9.82 ppm for a limited time is based on the agency’s finding that the interim specification presents no meaningful difference in cancer risk over a six-month time period when compared to a lifetime of exposure to NMBA at 0.96 ppm.6 The expectation is that this interim specification will prevent a shortage of Losartan and will also give sponsors a few months to develop a process to assure that they can provide the American public with NMBA-free losartan. Overall, the unexpected finding regarding the nitrosamines in ARBs has increased the work load of the pharmaceutical industry, especially API manufacturers as well as FDA, exponentially. It has also left the consumers wondering about the safety of the blood pressure medications they have been taking, sometimes for many years.

    While the entire pharmaceutical industry is holding its breath and waiting to see how nitrosamines in ARBs are eventually handled, questions have also arisen as to how a situation of this kind could be anticipated and possibly avoided in the future. Based on the structure of the “sartans” and the nature of the nitrosamines found in them, it can be concluded that the sources of the nitrosamines are not the degradation or the manufacturing process of the “sartans.” The sources lie in the impurities that may be present in the reagents and solvents used in the manufacturing of most of the “sartans” and, in some cases, the improper recycling of the solvents, which in turn can give rise to impurities.7 Sodium nitrite is a common agent used in the manufacturing of most of the “sartans.”

    As mentioned before, sodium nitrite undergoes a facile reaction under acidic pH with any amines, amides etc. that may be present impurities in the solvents, recycled solvents and reagents, to form the nitrosamines. Thus, it is imperative that manufacturers understand the possible source of nitrosamine formation in their manufacturing process and add proper controls to reduce the possibility of formation of these carcinogenic impurities. The pharmaceutical industry needs to look beyond the obvious and understand that the quality of the reagents and solvents, even those used relatively upstream in the manufacturing process, are critical for assuring the quality of the final drug substance.

    The questions that arise with nitrosamines and other mutagenic impurities in drug substances are what to do and where to start in order to anticipate and prevent these situations. In the case of nitrosamines, the following are examples of proactive steps that the drug substance manufacturers can take during the manufacturing of drug substance, which could lower the possibility of the presence of nitrosamines as impurities significantly:
    • Whenever the drug product is a secondary amine or any of the intermediates or impurities in the drug substance are secondary amines, it is beneficial to look for corresponding nitrosamines during the manufacturing process development.
    • When sodium nitrite is used in any step of the manufacturing process of a drug substance, an extensive evaluation should be done for all possible nitrosamines based on the starting materials, reagents and solvents. If sodium nitrite is used upstream in the manufacturing process, steps should be taken to make sure that it is very efficiently washed out.
    • When solvents such as DMF (dimethylformamide), DMA (dimethylacetamine), or DEA (diethylacetamide) are used in the manufacturing of a drug substance, it would be prudent to look for potential nitrosamines like NDMA and NDEA.
    • When a reagent has a secondary amine structure (e.g., diethanolamine or its derivatives are used as linkers in many synthetic process), it would be prudent to look for nitrosamines related to these amines.9
    • N-alkyl amides, carbamates can be nitrosated.1 So, one should be cognizant of the possibility of nitrosamines being formed, in case amides and carbamates are used as reagents or generated as intermediates in the synthetic scheme of the drug substance.
    • If a late-stage intermediate is considered a Regulatory Starting Material (RSM) and bought from an external vendor, it should be verified whether sodium nitrite has been used in any step of the manufacturing process of the RSM.

    As of now, it seems like an uphill task for the pharmaceutical industry to understand when and where nitrosamines may become present in drug products. However, with better understanding of their precursors and the conditions which facilitate their formation, the industry may be able to reach a point where it can curtail or even eliminate the possibility of nitrosamines appearing in pharmaceutical products.

    References
    1. Loeppky, R., N.; “Nitrosamine and N-Nitroso Compound Chemistry and Biochemistry: Advances and Perspectives”; ACS Symposium Series, Vol. 553, Chapter 1, pp. 1–18, March 28, 1994.
    2. Preussmann, R., et. al.; “N-Nitroso Carcinogens”; ACS Monograph; 1984, 182 (Chem. Carcinog., 2nd edition, Vol. 2), pp. 643-828
    3. Lijinsky, W., et. al.; “Comparative carcinogenesis by some aliphatic nitrosamines in Fischer rats”; Cancer Letters,  Vol. 14 (3), pp. 297-302, December 1981.
    4. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; “ICH Harmonised Guideline -  Assessment And Control Of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk, M7(R1)”; March 31, 2017, http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M7/M7_R1_Addendum_Step_4_2017_0331.pdf.
    5. International Agency for Research on Cancer; “IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Smokeless Tobacco and Some Tobacco-specific N-Nitrosamines”; Volume 89, 2007, https://monographs.iarc.fr/iarc-monographs-on-the-evaluation-of-carcinogenic-risks-to-humans-32/.
    6. U.S. Food and Drug Administration; “FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan”;; https://www.fda.gov/drugs/drugsafety/ucm613916.htm; updated as of April 4, 2019.
    7. U.S. Food and Drug Administration; “FDA News Release: FDA provides update on its ongoing investigation into ARB drug products; reports on finding of a new nitrosamine impurity in certain lots of losartan and product recall; March 1, 2019; ; https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm632425.htm.
    8. U.S. Food and Drug Administration; “Combined Direct Injection N-Nitrosodimethylamine (NDMA) and NNitrosodiethylamine (NDEA) Impurity Assay by GC/MS;; https://www.fda.gov/downloads/Drugs/DrugSafety/UCM623578.pdf; web accessed April 8, 2019.
    9. Loeppky, R. N., Erb, E., Srinivasan, A., and Yu, L.; “Nitrosamine and N-Nitroso Compound Chemistry and Biochemistry: Chemistry of Putative Intermediates in Bioactivation of -Oxidized Nitrosamines”; ACS Symposium Series, Vol. 553, Chapter 33, pp. 334-336, March 28, 1994.

    Aloka Srinivasan, Ph.D.
    Lachman Consultant Services

    Aloka Srinivasan, Ph.D., is Vice President, Regulatory Practice at Lachman Consultants who brings more than two decades of experience in the pharmaceutical industry, including nine years of progressive experience with the U.S. FDA in the Office of Generic Drugs. She provides strategic guidance to applicants in regulatory and chemistry, manufacturing and controls (CMC) for drug products and drug substances at all stages of development and for all types of regulatory submissions.
    Related Searches
    • api manufacturers
    • generic
    • study
    • fda
    Suggested For You
    Mogene Mogene
    Vetio Animal Health Vetio Animal Health
    5 ADC Manufacturing Challenges You Need To Know 5 ADC Manufacturing Challenges You Need To Know
    Manufacturing Strategy Keys for Success Manufacturing Strategy Keys for Success
    Process Validation in Biologics Development Process Validation in Biologics Development
    Lachman Consultants Names Compliance Services VP Lachman Consultants Names Compliance Services VP
    The Unfolding Pharma Product Mix The Unfolding Pharma Product Mix
    Pii Receives EIR From FDA Pii Receives EIR From FDA
    Cellectis to Build Mfg. Facility in North Carolina Cellectis to Build Mfg. Facility in North Carolina
    Support Services Support Services
    FDA’s Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition an FDA’s Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition an
    Oral Solids Endure & Evolve Oral Solids Endure & Evolve
    Early Development Trends Early Development Trends
    Catalent Enters Clinical Supply Partnership with Adial Catalent Enters Clinical Supply Partnership with Adial
    Former FDA Senior Executives Join PAREXEL Former FDA Senior Executives Join PAREXEL

    Related Buyers Guide Companies

    • Mogene

      ...
      Craig Morley, CEO 11.17.20

    • Vetio Animal Health

      Vetio Animal Health

      ...
      John Kane, CEO 10.24.19

    • 5 ADC Manufacturing Challenges You Need To Know

      5 ADC Manufacturing Challenges You Need To Know

      Below are five key areas where pharmaceutical manufacturers may face the biggest uphill battles.


    • cGMP Manufacture
      Manufacturing Strategy Keys for Success

      Manufacturing Strategy Keys for Success

      One size fits all is rarely an appropriate drug manufacturing strategy.
      Oskar Gold, Vetter Pharma International GmbH 05.07.19

    • Biologics, Proteins, Vaccines | Process Validation
      Process Validation in Biologics Development

      Process Validation in Biologics Development

      Strategies for successful process validation in the wake of faster approval timelines.
      Victor Vinci and Claudia Berdugo-Davis, Catalent Biologics 05.07.19

    Loading, Please Wait..
    Trending
    • Aurigene Expands Biologics CDMO Capacity
    • Contract Pharma
    • Catalent Adds New Cryogenic Capabilities At Japanese Facility
    • Societal CDMO Partners With Atossa Therapeutics
    • Videobite: Contract Pharma Sits Down with Ryan Lake of Societal CDMO
    Breaking News
    • Catalent Adds New Cryogenic Capabilities at Japanese Facility
    • Lifecore Biomedical Enters into $150M New Financing Deal
    • WuXi Biologics Receives 2023 ISPE Facility of the Year Award
    • Thermo Fisher Expands Steriles Facility in Asia-Pacific Region
    • GHO Capital, Partners Group Invest in Sterling Pharma Solutions
    View Breaking News >
    CURRENT ISSUE

    May 2023

    • New Modalities Hog the Limelight
    • Cell and Gene Therapy is Coming of Age
    • Demand Surges for Cell and Gene Therapy Contract Manufacturing
    • Embracing a New Reality
    • Japan: A Unique Opportunity for Regenerative Medicines and Cell & Gene Therapies
    • Single-Use Technologies Enable Biologic Scaling
    • Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    • FTEs in Drug Discovery
    • Digital Transformation in Pharma
    • What is a Manufacturing Ecosystem and Why are They Growing?
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Premium Label & Packaging Solutions Receives Safe Quality Food (SQF) Certification
    Inulinase Enzymes May Benefit Gut Symptoms of FODMAP Digestion
    Verdure Sciences’ Boswellia Ingredient Receives USP Verification
    Coatings World

    Latest Breaking News From Coatings World

    OQ Chemicals Launches Cost-Cutting Program and Organizational Realignment in Germany
    BASF Strengthens R&D with More Powerful Supercomputer
    Safic-Alcan Expands its Presence in Africa with the Launch of Safic-Alcan East Africa in Kenya
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Vascular Surgeon Imprisoned and Fined for Decade-Long Healthcare Fraud
    Remote Monitoring, Digital Health Help Advance Wound Care Treatment
    MLM Biologics Developing Wound Infection Prevention Device for Military
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Catalent Adds New Cryogenic Capabilities at Japanese Facility
    Lifecore Biomedical Enters into $150M New Financing Deal
    WuXi Biologics Receives 2023 ISPE Facility of the Year Award
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    How Robots & Artificial Intelligence are Transforming Unilever's Material Innovation Factory
    Top 10 Most Popular Hair Care Brands in the U.S.—Ranked by Searches
    Aloette Cosmetics Launches Daily Mineral Shield Sunscreen
    Happi

    Latest Breaking News From Happi

    Revieve Launches Beauty Technology Platform on Google Cloud Marketplace
    BBW’s Fabric Softener Launch, Ameon’s New Ambassador
    Mielle Organics Taps Angel Reese as New Ambassador
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: INX Digital, Mexar and hubergroup Top This Week’s Stories
    Richnerstutz AG Acquires an EFI VUTEk Q5r Superwide Roll-to-Roll Printer
    BASF Strengthens Its R&D with More Powerful Supercomputer
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Mactac acquires Label Supply, Beontag grows and more
    Sun Chemical releases Spring 2023 Regulatory Newsletter
    Tageos unveils new RAIN RFID inlays
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Weekly Recap: Corman, Tosama Develop Biodegradable Plastic Tampon Applicator, Trevira Changes Name
    Suominen Appoints SVP, Transformation Management Office
    Minnesota Signs PFAS Ban in Consumer Products
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    AlloSource Launches AlloMend Duo Acellular Dermal Matrix
    TendoNova Inks Partnership With AcCELLerated Biologics
    Stryker Achieves First Surgeries Using Q Guidance System with Cranial Guidance Software
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: Smart Skis, Universal Display Top This Week’s Stories
    Wiliot Appoints Antony Yousefian as VP of Climate & Circularity
    HID Unveils Eco-friendly Bamboo Access Cards

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login